Khiron Life Sciences Corp. (TSXV:KHRN) was featured in a speculative buy report by Canaccord Genuity, an independent full-service financial services firm. The basis for the report was based on Khiron’s first mover advantage and the emerging legalized cannabis markets in Latin America.

Khiron operates out of Colombia, which offers optimal growing conditions, cost advantages, liberal prescribing regulations and a medical cannabis market comprised of approximately 700,000 patients. The report concluded, that the Latin American cannabis market has a potential to make $8 to $9 billion annually. The report highlighted Khiron’s facilities in Colombia, which will be able to produce approximately 16,900 kilograms of cannabis per year and will be able to service approximately 100,000 patients. The company is expecting its first harvest in late 2018 and expects sales to commence in early 2019.


The report also touched on Khiron’s established medical cannabis patient network of approximately 400,000 patients. Their patient base has been developed through their education platform and their strategic alliances with 3,000 doctors. The company is also in the process of closing an acquisition for the ILANS clinics, which could bring an additional 100,000 patients to its portfolio. The first clinic is expected to be operational by the end of 2018 depending on the closing of the acquisition.

These two factors, among others, provided the basis for the report’s $3 speculative buy rating.

 

Click here to connect with Khiron Life Sciences Corp. (TSXV:KHRN) for an Investor Presentation.

Source: canaccordgenuity.bluematrix.com

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aurora securities between February 13, 2020, and September 4, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/acb .

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Keep reading... Show less

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less